SHANDONG BOAN BIOTECH.H 1 Market Cap ($244.46 Million)
Market Cap & Net Worth: SHANDONG BOAN BIOTECH.H 1 (UJ9)
SHANDONG BOAN BIOTECH.H 1 market cap. SHANDONG BOAN BIOTECH.H 1 (F:UJ9) has a market capitalization of $244.46 Million (€209.10 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #15352 globally and #1501 in its home market, demonstrating a -5.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANDONG BOAN BIOTECH.H 1's stock price €0.34 by its total outstanding shares 622333694 (622.33 Million). Also see UJ9 operating cash flow for how efficiently the company converts equity into cash flow.
SHANDONG BOAN BIOTECH.H 1 Market Cap History (2023–2026)
SHANDONG BOAN BIOTECH.H 1 market cap history from 2023 to 2026. Data shows change from $1.50 Billion to $244.46 Million (-35.73% CAGR). Check today's stock price for SHANDONG BOAN BIOTECH.H 1 for real-time trading data and today's change.
SHANDONG BOAN BIOTECH.H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANDONG BOAN BIOTECH.H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore UJ9 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.78x
SHANDONG BOAN BIOTECH.H 1's market cap is 0.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
86.06x
SHANDONG BOAN BIOTECH.H 1's market cap is 86.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.50 Billion | $618.13 Million | -$119.38 Million | 2.42x | N/A |
| 2024 | $771.23 Million | $726.32 Million | $73.19 Million | 1.06x | 10.54x |
| 2025 | $614.80 Million | $784.82 Million | $7.14 Million | 0.78x | 86.06x |
Competitor Companies of UJ9 by Market Capitalization
Companies near SHANDONG BOAN BIOTECH.H 1 in the global market cap rankings as of November 4, 2026. Also see SHANDONG BOAN BIOTECH.H 1 (UJ9) total assets for a full breakdown of the balance sheet.
Key companies related to SHANDONG BOAN BIOTECH.H 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of SHANDONG BOAN BIOTECH.H 1 (2023–2026)
Market capitalization of SHANDONG BOAN BIOTECH.H 1 from 2023 to today. Between 2023 and today, SHANDONG BOAN BIOTECH.H 1's market cap moved from $1.50 Billion to $ 244.46 Million, with a yearly change of -35.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €244.46 Million | -60.24% |
| 2025 | €614.80 Million | -20.28% |
| 2024 | €771.23 Million | -48.54% |
| 2023 | €1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of SHANDONG BOAN BIOTECH.H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.46 Million USD |
| MoneyControl | $244.46 Million USD |
| MarketWatch | $244.46 Million USD |
| marketcap.company | $244.46 Million USD |
| Reuters | $244.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more